

# Resource Summary Report

Generated by PRECISE-TBI on Aug 10, 2026

## CD3 Antibody, anti-human, VioBlue®, REAfinity™

RRID:AB\_2726687

Type: Antibody

### Proper Citation

Miltenyi Biotec Cat# 130-114-519, RRID:AB\_2726687

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2726687](http://antibodyregistry.org/AB_2726687)

**Proper Citation:** Miltenyi Biotec Cat# 130-114-519, RRID:AB\_2726687

**Target Antigen:** CD3

**Host Organism:** human

**Clonality:** monoclonal

**Comments:** Info: This product is a higher concentration for optimized use in multicolor flow cytometry panels. It replaces product cat # 130-110-460. (RRID:AB\_2657065).

**Antibody Name:** CD3 Antibody, anti-human, VioBlue®, REAfinity™

**Description:** This monoclonal targets CD3

**Target Organism:** human

**Clone ID:** clone REA613

**Antibody ID:** AB\_2726687

**Vendor:** Miltenyi Biotec

**Catalog Number:** 130-114-519

**Record Creation Time:** 20250820T003100+0000

**Record Last Update:** 20250820T082835+0000

### Ratings and Alerts

No rating or validation information has been found for CD3 Antibody, anti-human, VioBlue®, REAfinity™.

No alerts have been found for CD3 Antibody, anti-human, VioBlue®, REAfinity™.

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 3 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [PRECISE-TBI](#) .

Vandoren R, et al. (2026) AIRRWAS integrates TCR-microbiome data to reveal how the gut microbiome shapes the circulating and mucosal T cell repertoire. Cell reports, 45(6), 117479.

Desveaux JM, et al. (2026) Neutralizing human monoclonal antibodies that target the PcrV component of the type III secretion system of Pseudomonas aeruginosa act through distinct mechanisms. eLife, 14.

David M, et al. (2025) Enhanced anti-tumor activity by zinc finger repressor-driven epigenetic silencing of immune checkpoints and TGFBR2 in CAR-T cells and TILs. Molecular therapy. Oncology, 33(2), 200989.